NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries
Key Highlights
- ➤NeOnc (NTHI) plans approximately 500-patient trial across 30 hospitals in three countries
- ➤NEO100 uses intranasal delivery designed to bypass the blood-brain barrier
- ➤NeOnc reported radiographic remission in six of 25 patients
- ➤NEO100 evaluation targets patients with IDH-mutated tumors
Expert Statements
Wallace, Doctor treating a NeOnc patient
“We can’t see it, actually, at this moment.”
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is setting its sights on a substantially larger international clinical effort, outlining plans for a trial targeting approximately 500 patients across 30 hospitals in three countries during a discussion on Health Uncensored with Dr. Drew, on Fox Business Network.
The proposed expansion brings fresh attention to NeOnc’s effort to address one of brain cancer treatment’s toughest challenges: delivering potential therapies into the brain. The discussion connected the scale of the company’s ambitions with its investigational treatment strategy, early clinical observations and the patients whose experiences give that work urgency.
Get started
Create a free account to read the full story.